Generic Medicine Info
May be taken with or without food.
Sinus bradycardia, cardiogenic shock, hypotension, metabolic acidosis, 2nd- or 3rd-degree heart block, severe peripheral arterial disease, sick sinus syndrome, uncontrolled cardiac failure, untreated phaeochromocytoma.
Special Precautions
Patient with poor cardiac reserve, compensated heart failure, Prinzmetal's angina, peripheral vascular disease, Raynaud's phenomenon, 1st-degree heart block, bronchospastic disease, history of anaphylactic reaction to allergens; diabetes mellitus, myasthenia gravis, psoriasis. Patient undergoing surgery. Avoid abrupt withdrawal. May mask the signs and symptoms of hypoglycaemia and hyperthyroidism (particularly tachycardia). Elderly. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure and heart rate (before and after initiation of therapy and following any dose changes); serum glucose (in diabetic patients); renal function. Obtain ECG when used for acute cardiac treatment.
Adverse Reactions
Significant: Bradycardia; may exacerbate angina and precipitate MI and ventricular arrhythmias after abrupt discontinuation (in patients with angina); may precipitate or aggravate peripheral arterial insufficiency. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Nausea, diarrhoea, dry mouth. General disorders and administration site conditions: Fatigue, lethargy. Immune system disorders: Hypersensitivity reaction (including urticaria and angioedema). Investigations: Elevated transaminase levels. Musculoskeletal and connective tissue disorders: Lupus-like syndrome. Nervous system disorders: Dizziness, drowsiness. Psychiatric disorders: Sleep disturbances, depression. Skin and subcutaneous tissue disorders: Rarely, exacerbation of psoriasis, psoriasiform skin reactions. Vascular disorders: Cold extremities, hypotension, orthostatic hypotension.
Drug Interactions
May increase the risk of severe hypotension, bradycardia, and heart failure with diltiazem or verapamil. Additive hypotensive effect with catecholamine-depleting agents (e.g. reserpine) and other Ca channel blockers (e.g. nifedipine). May increase the risk of bradycardia when given with digitalis glycosides. May enhance the rebound hypertension that can follow the withdrawal of clonidine. Potentiates the effect on atrial conduction time and induces a negative inotropic effect with class I antiarrhythmic agents (e.g. disopyramide) and amiodarone. May diminish the therapeutic effect of sympathomimetic agents (e.g. epinephrine). May potentiate the hypoglycaemic effects of insulin and oral antidiabetic agents. Concomitant use with NSAIDs (e.g. ibuprofen, indometacin) may decrease the hypotensive effect of atenolol. May increase the risk of hypotension and attenuate reflex tachycardia with anaesthetic drugs (e.g. methoxyflurane).
CIMS Class
Anti-Anginal Drugs / Beta-Blockers
ATC Classification
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on atenolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in